Sign in Subscribe
United States. Securities and Exchange Commission

Moderna, Inc. Files SEC Form 4

Strategic Insights

— 1 min read

Moderna, Inc., a biotechnology company focused on the development of mRNA therapeutics, has filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on December 30, 2022. The SEC filing provides information on the company's director, officer, or owner of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act. The document reports a single filing, which includes details on the reporting person's relationship to the company and purchases and sales of equity securities.

Key Takeaways:

  • Moderna, Inc. filed a Form 4 with the SEC on December 30, 2022, as required by the '34 Act for companies with over ten percent ownership.
  • The filing includes information on the company's SIC code, 2836, for biological products (no diagnostic substances).
  • The contact information for the company is 200 Technology Square, Cambridge, MA 02139, and can be reached at 617-714-6500.
  • Form 4 is used to report changes in beneficial ownership of securities, whereas Form 3 is for the initial statement and Form 5 is for the annual statement.
  • Sec filer information includes: Moderna, Inc. (No company abbreviation listed), filing company for small business, 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139, (617-714-6500).
  • The company's SEC filing is a formal document submitted to the SEC by publicly-traded companies, and can be found on the SEC website at https://www.sec.gov/Archives/edgar/data/1682852/0001127602-22-028352-index.html.

Statistics:

  • Date of filing: December 30, 2022.
  • SEC filing number: 0001127602-22-028352.
  • Form type: Form 4.
  • Company ID: 1682852.

Sources:

  • NewsRx - 2023 JAN 16, "Moderna, Inc. files SEC Form 4" (Note: only the actual publication date of 2023 JAN 16 is usable as the source material does not provide the date of the actual SEC filing).

Read more